Phase II study of combination therapy with Irinotecan and S-1 in patients with progressive colorectal cancer after FOLFOX regimen

ABSTRACT: Interventions: Irinotecan+S-1, repeated every 3 weeks. Primary outcome(s): RR Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Advanced/recurrent Colorectal Cancer

PROVIDER: 2616834 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR